{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:34:50Z","timestamp":1791999290925,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.yrtph.2026.106155","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:27:47Z","timestamp":1780842467000},"page":"106155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1218-293X","authenticated-orcid":false,"given":"Christian","family":"Novello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"De Marzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mastrocola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Bassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Boltri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2026.106155_bib1","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1021\/acs.joc.0c02774","article-title":"An organic chemist's guide to N -Nitrosamines: their structure, reactivity, and role as contaminants","volume":"86","author":"Beard","year":"2021","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.yrtph.2026.106155_bib2","article-title":"Developing structure-activity relationships for N-nitrosamine activity","volume":"20","author":"Cross","year":"2021","journal-title":"Comput. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106155_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yrtph.2026.106155_bib4","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1021\/acs.chemrestox.1c00369","article-title":"Practical and science-based strategy for establishing acceptable intakes for drug product N -Nitrosamine impurities","volume":"35","author":"Dobo","year":"2022","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106155_bib6","series-title":"Read-Across Assessment Framework (RAAF), ECHA-17-R-01-EN","year":"2017"},{"key":"10.1016\/j.yrtph.2026.106155_bib7","article-title":"Guidance on the use of read\u2010across for chemical safety assessment in food and feed","year":"2025","journal-title":"EFSA J."},{"key":"10.1016\/j.yrtph.2026.106155_bib8","series-title":"Questions and Answers for Marketing Authorisation holders\/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726\/2004 Referral on Nitrosamine Impurities in Human Medicinal Products (No. EMA\/409815\/2020 Rev.23)","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106155_bib9","series-title":"Control of Nitrosamine Impurities in Human Drugs","year":"2024"},{"key":"10.1016\/j.yrtph.2026.106155_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105505","article-title":"Nitrosamine acceptable intakes should consider variation in molecular weight: the implication of stoichiometric DNA damage","volume":"145","author":"Fine","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106155_bib11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0165-1110(87)90026-1","article-title":"N-nitrosamines: bacterial mutagenesis and in vitro metabolism","volume":"186","author":"Guttenplan","year":"1987","journal-title":"Mutat. Res. Rev. Genet. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106155_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2019.104403","article-title":"Genetic toxicology in silico protocol","volume":"107","author":"Hasselgren","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106155_bib13","series-title":"Guidance on Nitrosamine Impurities in Medications - Evaluating and Managing the Risks of N-nitrosamine Impurities in Human Pharmaceutical, Biological and Radiopharmaceutical Products","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106155_bib14","volume":"vol. 17","year":"1978"},{"key":"10.1016\/j.yrtph.2026.106155_bib15","series-title":"ICH Harmonised Guideline","article-title":"ICH guideline M7 (R2). Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk (No. EMA\/CHMP\/ICH\/83812\/2013)","year":"2023"},{"key":"10.1016\/j.yrtph.2026.106155_bib16","series-title":"ICH Q3A (R2) Impurities in New Drug Substances (No. CPMP\/ICH\/2737\/99)","year":"2006"},{"key":"10.1016\/j.yrtph.2026.106155_bib17","series-title":"ICH Q3B (R2) Impurities in New Drug Products (No. CPMP\/ICH\/2738\/99), ICH Harmonised Tripartite Guideline","year":"2006"},{"key":"10.1016\/j.yrtph.2026.106155_bib18","series-title":"Leadscope Model Applier","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106155_bib19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2131\/jts.21.SupplementI_241","article-title":"Mutagenicity Studies of Prulifloxacin (nm441) and the Active Metabolite (nm394)","volume":"21","author":"Iwakura","year":"1996","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.yrtph.2026.106155_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.yrtph.2007.01.006","article-title":"An evaluation of the sensitivity of the Ames assay to discern low-level mutagenic impurities","volume":"48","author":"Kenyon","year":"2007","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106155_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2024.105640","article-title":"Determining recommended acceptable intake limits for N-Nitrosamine impurities in pharmaceuticals: development and application of the Carcinogenic Potency Categorization Approach (CPCA)","author":"Kruhlak","year":"2024","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106155_bib22","first-page":"4559","article-title":"Metabolic activation and DNA interactions of carcinogenic N-Nitrosamines to which humans are commonly exposed","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Math. Stat."},{"key":"10.1016\/j.yrtph.2026.106155_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/BF00144269","article-title":"Structure-activity relations in carcinogenesis by N-nitroso compounds","volume":"6","author":"Lijinsky","year":"1987","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.yrtph.2026.106155_bib25","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.yrtph.2005.12.001","article-title":"A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity","volume":"44","author":"M\u00fcller","year":"2006","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106155_bib27","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/acs.oprd.3c00100","article-title":"The nitrosamine \u201cSaga\u201d: lessons learned from five years of scrutiny","volume":"27","author":"Nudelman","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2026.106155_bib28","series-title":"Guidance on Grouping of Chemicals","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106155_bib29","series-title":"The OECD QSAR Toolbox V. 4.8.2","year":"2025"},{"key":"10.1016\/j.yrtph.2026.106155_bib31","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.2c01498","article-title":"Strategies for assessing acceptable intakes for novel N -Nitrosamines derived from active pharmaceutical ingredients","author":"Ponting","year":"2022","journal-title":"J. Med. Chem. acs.jmedchem.2c01498."},{"key":"10.1016\/j.yrtph.2026.106155_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2025.106009","article-title":"Establishing best practice for N-nitrosamine read-across and surrogate selection","volume":"166","author":"Ponting","year":"2026","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106155_bib30","doi-asserted-by":"crossref","DOI":"10.1021\/acs.oprd.3c00008","article-title":"Drawing a line: where might the cohort of concern end?","author":"Ponting","year":"2023","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.yrtph.2026.106155_bib33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijantimicag.2010.11.032","article-title":"Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections","volume":"37","author":"Rafailidis","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.yrtph.2026.106155_bib34","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.xphs.2022.11.013","article-title":"The landscape of potential small and drug substance related nitrosamines in pharmaceuticals","volume":"112","author":"Schlingemann","year":"2023","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.yrtph.2026.106155_bib35","article-title":"Risk assessment of N-nitrosamines in food","volume":"21","author":"Schrenk","year":"2023","journal-title":"EFSA J."},{"key":"10.1016\/j.yrtph.2026.106155_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.comtox.2018.10.003","article-title":"Assessing uncertainty in read-across: questions to evaluate toxicity predictions based on knowledge gained from case studies","volume":"9","author":"Schultz","year":"2019","journal-title":"Comput. Toxicol."},{"key":"10.1016\/j.yrtph.2026.106155_bib37","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1021\/acs.chemrestox.2c00199","article-title":"What makes a potent nitrosamine? Statistical validation of expert-derived structure\u2013activity relationships","volume":"35","author":"Thomas","year":"2022","journal-title":"Chem. Res. Toxicol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026001285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:34:28Z","timestamp":1785508468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026001285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S0273230026001285"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106155","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of read-across to data-poor N-nitrosamines: N-nitroso-ulifloxacin, a case study","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106155"}}